Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Overexpression of BLM promotes DNA damage and increased sensitivity to platinum salts in triple-negative breast and serous ovarian cancers.

Birkbak NJ, Li Y, Pathania S, Greene-Colozzi A, Dreze M, Bowman-Colin C, Sztupinszki Z, Krzystanek M, Diossy M, Tung N, Ryan PD, Garber JE, Silver DP, Iglehart JD, Wang ZC, Szuts D, Szallasi Z, Richardson AL.

Ann Oncol. 2018 Apr 1;29(4):903-909. doi: 10.1093/annonc/mdy049.

2.

Reply to Kennedy: Historical evidence supports remarkable breaking wave heights.

Dewey JF, Ryan PD.

Proc Natl Acad Sci U S A. 2018 Feb 27;115(9):E1939. doi: 10.1073/pnas.1722292115. Epub 2018 Feb 8. No abstract available.

3.

Storm, rogue wave, or tsunami origin for megaclast deposits in western Ireland and North Island, New Zealand?

Dewey JF, Ryan PD.

Proc Natl Acad Sci U S A. 2017 Dec 12;114(50):E10639-E10647. doi: 10.1073/pnas.1713233114. Epub 2017 Nov 27.

4.

Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.

Telli ML, Timms KM, Reid J, Hennessy B, Mills GB, Jensen KC, Szallasi Z, Barry WT, Winer EP, Tung NM, Isakoff SJ, Ryan PD, Greene-Colozzi A, Gutin A, Sangale Z, Iliev D, Neff C, Abkevich V, Jones JT, Lanchbury JS, Hartman AR, Garber JE, Ford JM, Silver DP, Richardson AL.

Clin Cancer Res. 2016 Aug 1;22(15):3764-73. doi: 10.1158/1078-0432.CCR-15-2477. Epub 2016 Mar 8.

5.

TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer.

Isakoff SJ, Mayer EL, He L, Traina TA, Carey LA, Krag KJ, Rugo HS, Liu MC, Stearns V, Come SE, Timms KM, Hartman AR, Borger DR, Finkelstein DM, Garber JE, Ryan PD, Winer EP, Goss PE, Ellisen LW.

J Clin Oncol. 2015 Jun 10;33(17):1902-9. doi: 10.1200/JCO.2014.57.6660. Epub 2015 Apr 6.

6.

Multifocal and multicentric breast cancer is associated with increased local recurrence regardless of surgery type.

Shaikh T, Tam TY, Li T, Hayes SB, Goldstein L, Bleicher R, Boraas M, Sigurdson E, Ryan PD, Anderson P.

Breast J. 2015 Mar-Apr;21(2):121-6. doi: 10.1111/tbj.12366. Epub 2015 Jan 17.

PMID:
25597248
7.

Drug withdrawal in women with progressive metastatic breast cancer while on aromatase inhibitor therapy.

Chavarri-Guerra Y, Higgins MJ, Szymonifka J, Cigler T, Liedke P, Partridge A, Ligibel J, Come SE, Finkelstein D, Ryan PD, Goss PE.

Br J Cancer. 2014 Nov 25;111(11):2046-50. doi: 10.1038/bjc.2014.502. Epub 2014 Sep 18.

8.

Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors.

Balmaña J, Tung NM, Isakoff SJ, Graña B, Ryan PD, Saura C, Lowe ES, Frewer P, Winer E, Baselga J, Garber JE.

Ann Oncol. 2014 Aug;25(8):1656-63. doi: 10.1093/annonc/mdu187. Epub 2014 May 14.

PMID:
24827126
9.

Intermittent letrozole therapy for metastatic breast cancer: case reports and literature review.

Fan L, Liedke PE, Isakoff SJ, St Louis J, Ryan PD, Goss PE.

Clin Breast Cancer. 2014 Apr;14(2):e41-5. doi: 10.1016/j.clbc.2013.10.009. Epub 2013 Oct 25. Review. No abstract available.

PMID:
24342729
10.

Young adult daughters of BRCA1/2 positive mothers: what do they know about hereditary cancer and how much do they worry?

Patenaude AF, Tung N, Ryan PD, Ellisen LW, Hewitt L, Schneider KA, Tercyak KP, Aldridge J, Garber JE.

Psychooncology. 2013 Sep;22(9):2024-31. doi: 10.1002/pon.3257. Epub 2013 Feb 18.

PMID:
23417902
11.

Cost-effectiveness of alternating magnetic resonance imaging and digital mammography screening in BRCA1 and BRCA2 gene mutation carriers.

Cott Chubiz JE, Lee JM, Gilmore ME, Kong CY, Lowry KP, Halpern EF, McMahon PM, Ryan PD, Gazelle GS.

Cancer. 2013 Mar 15;119(6):1266-76. doi: 10.1002/cncr.27864. Epub 2012 Nov 26.

12.
13.

Faciocutaneous cancer syndromes: spot the diagnosis.

Morrison PJ, Ryan PD.

Oncologist. 2012;17(7):886-7. doi: 10.1634/theoncologist.2012-0171. Epub 2012 Jun 15. No abstract available.

14.

Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents.

Birkbak NJ, Wang ZC, Kim JY, Eklund AC, Li Q, Tian R, Bowman-Colin C, Li Y, Greene-Colozzi A, Iglehart JD, Tung N, Ryan PD, Garber JE, Silver DP, Szallasi Z, Richardson AL.

Cancer Discov. 2012 Apr;2(4):366-375. doi: 10.1158/2159-8290.CD-11-0206. Epub 2012 Mar 22. Erratum in: Cancer Discov. 2013 Aug;3(8):952.

15.

Which individuals undergoing BRACAnalysis need BART testing?

Shannon KM, Rodgers LH, Chan-Smutko G, Patel D, Gabree M, Ryan PD.

Cancer Genet. 2011 Aug;204(8):416-22. doi: 10.1016/j.cancergen.2011.07.005.

PMID:
21962891
16.

Annual screening strategies in BRCA1 and BRCA2 gene mutation carriers: a comparative effectiveness analysis.

Lowry KP, Lee JM, Kong CY, McMahon PM, Gilmore ME, Cott Chubiz JE, Pisano ED, Gatsonis C, Ryan PD, Ozanne EM, Gazelle GS.

Cancer. 2012 Apr 15;118(8):2021-30. doi: 10.1002/cncr.26424. Epub 2011 Sep 20. Erratum in: Cancer. 2012 Nov 1;118(21):5448.

17.

Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancers.

Tung N, Miron A, Schnitt SJ, Gautam S, Fetten K, Kaplan J, Yassin Y, Buraimoh A, Kim JY, Szász AM, Tian R, Wang ZC, Collins LC, Brock J, Krag K, Legare RD, Sgroi D, Ryan PD, Silver DP, Garber JE, Richardson AL.

Breast Cancer Res. 2010;12(6):R95. doi: 10.1186/bcr2776. Epub 2010 Nov 16.

18.

Germline mutations in CDH1 are infrequent in women with early-onset or familial lobular breast cancers.

Schrader KA, Masciari S, Boyd N, Salamanca C, Senz J, Saunders DN, Yorida E, Maines-Bandiera S, Kaurah P, Tung N, Robson ME, Ryan PD, Olopade OI, Domchek SM, Ford J, Isaacs C, Brown P, Balmana J, Razzak AR, Miron P, Coffey K, Terry MB, John EM, Andrulis IL, Knight JA, O'Malley FP, Daly M, Bender P; kConFab, Moore R, Southey MC, Hopper JL, Garber JE, Huntsman DG.

J Med Genet. 2011 Jan;48(1):64-8. doi: 10.1136/jmg.2010.079814. Epub 2010 Oct 4.

19.

Cost-effectiveness of breast MR imaging and screen-film mammography for screening BRCA1 gene mutation carriers.

Lee JM, McMahon PM, Kong CY, Kopans DB, Ryan PD, Ozanne EM, Halpern EF, Gazelle GS.

Radiology. 2010 Mar;254(3):793-800. doi: 10.1148/radiol.09091086.

20.

Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features.

Tung N, Wang Y, Collins LC, Kaplan J, Li H, Gelman R, Comander AH, Gallagher B, Fetten K, Krag K, Stoeckert KA, Legare RD, Sgroi D, Ryan PD, Garber JE, Schnitt SJ.

Breast Cancer Res. 2010;12(1):R12. doi: 10.1186/bcr2478. Epub 2010 Feb 11.

21.

Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer.

Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q, Juul N, Leong CO, Calogrias D, Buraimoh A, Fatima A, Gelman RS, Ryan PD, Tung NM, De Nicolo A, Ganesan S, Miron A, Colin C, Sgroi DC, Ellisen LW, Winer EP, Garber JE.

J Clin Oncol. 2010 Mar 1;28(7):1145-53. doi: 10.1200/JCO.2009.22.4725. Epub 2010 Jan 25.

22.

VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy.

Burstein HJ, Chen YH, Parker LM, Savoie J, Younger J, Kuter I, Ryan PD, Garber JE, Chen H, Campos SM, Shulman LN, Harris LN, Gelman R, Winer EP.

Clin Cancer Res. 2008 Dec 1;14(23):7871-7. doi: 10.1158/1078-0432.CCR-08-0593.

23.

Analysis of the MammaPrint breast cancer assay in a predominantly postmenopausal cohort.

Wittner BS, Sgroi DC, Ryan PD, Bruinsma TJ, Glas AM, Male A, Dahiya S, Habin K, Bernards R, Haber DA, Van't Veer LJ, Ramaswamy S.

Clin Cancer Res. 2008 May 15;14(10):2988-93. doi: 10.1158/1078-0432.CCR-07-4723.

24.

Professional challenges in cancer genetic testing: who is the patient?

Chan-Smutko G, Patel D, Shannon KM, Ryan PD.

Oncologist. 2008 Mar;13(3):232-8. doi: 10.1634/theoncologist.2007-0203.

25.

Breast cancer screening in BRCA1 mutation carriers: effectiveness of MR imaging--Markov Monte Carlo decision analysis.

Lee JM, Kopans DB, McMahon PM, Halpern EF, Ryan PD, Weinstein MC, Gazelle GS.

Radiology. 2008 Mar;246(3):763-71. doi: 10.1148/radiol.2463070224.

PMID:
18309013
26.

The emerging role of the insulin-like growth factor pathway as a therapeutic target in cancer.

Ryan PD, Goss PE.

Oncologist. 2008 Jan;13(1):16-24. doi: 10.1634/theoncologist.2007-0199. Review.

27.

Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer.

Harris LN, You F, Schnitt SJ, Witkiewicz A, Lu X, Sgroi D, Ryan PD, Come SE, Burstein HJ, Lesnikoski BA, Kamma M, Friedman PN, Gelman R, Iglehart JD, Winer EP.

Clin Cancer Res. 2007 Feb 15;13(4):1198-207.

28.

Uptake of BRCA1 rearrangement panel testing: in individuals previously tested for BRCA1/2 mutations.

Shannon KM, Muzikansky A, Chan-Smutko G, Niendorf KB, Ryan PD.

Genet Med. 2006 Dec;8(12):740-5.

PMID:
17172936
29.

Adjuvant hormonal therapy in peri- and postmenopausal breast cancer.

Ryan PD, Goss PE.

Oncologist. 2006 Jul-Aug;11(7):718-31. Review.

30.

Case records of the Massachusetts General Hospital. Case 6-2006. A 71-year-old woman with urinary incontinence and a mass in the bladder.

Ryan PD, Harisinghani M, Lerwill MF, Kaufman DS.

N Engl J Med. 2006 Feb 23;354(8):850-6. No abstract available.

PMID:
16495398
31.

The evolving role of aromatase inhibitors in the treatment of early-stage breast cancer.

Ryan PD, Goss PE.

Nat Clin Pract Oncol. 2005 Dec;2(12):596-7. No abstract available.

PMID:
16341095
32.

Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy.

Burstein HJ, Parker LM, Keshaviah A, Doherty J, Partridge AH, Schapira L, Ryan PD, Younger J, Harris LN, Moy B, Come SE, Schumer ST, Bunnell CA, Haldoupis M, Gelman R, Winer EP.

J Clin Oncol. 2005 Nov 20;23(33):8340-7.

PMID:
16293865
33.

Case records of the Massachusetts General Hospital. Case 24-2005. A 58-year-old woman with early-stage estrogen-receptor-positive breast cancer.

Ryan PD, Kopans DB, Sgroi DC.

N Engl J Med. 2005 Aug 11;353(6):617-22. No abstract available.

PMID:
16093471
34.

RE: A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen.

Sgroi DC, Haber DA, Ryan PD, Ma XJ, Erlander MG.

Cancer Cell. 2004 Nov;6(5):445. No abstract available.

35.

A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen.

Ma XJ, Wang Z, Ryan PD, Isakoff SJ, Barmettler A, Fuller A, Muir B, Mohapatra G, Salunga R, Tuggle JT, Tran Y, Tran D, Tassin A, Amon P, Wang W, Wang W, Enright E, Stecker K, Estepa-Sabal E, Smith B, Younger J, Balis U, Michaelson J, Bhan A, Habin K, Baer TM, Brugge J, Haber DA, Erlander MG, Sgroi DC.

Cancer Cell. 2004 Jun;5(6):607-16.

37.

Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.

Burstein HJ, Harris LN, Marcom PK, Lambert-Falls R, Havlin K, Overmoyer B, Friedlander RJ Jr, Gargiulo J, Strenger R, Vogel CL, Ryan PD, Ellis MJ, Nunes RA, Bunnell CA, Campos SM, Hallor M, Gelman R, Winer EP.

J Clin Oncol. 2003 Aug 1;21(15):2889-95.

PMID:
12885806
38.

Women's interest in chemoprevention for breast cancer.

Bastian LA, Lipkus IM, Kuchibhatla MN, Weng HH, Halabi S, Ryan PD, Skinner CS, Rimer BK.

Arch Intern Med. 2001 Jul 9;161(13):1639-44.

PMID:
11434796
39.

On receptor inhibitors and chemotherapy.

Ryan PD, Chabner BA.

Clin Cancer Res. 2000 Dec;6(12):4607-9. Review. No abstract available.

40.

Supplemental Content

Support Center